• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

    1.995 -0.025 (-1.24%)
    Streaming Delayed Price Updated: 2:29 PM EDT, Jul 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 621,952
    Open 2.020
    Bid (Size) 1.990 (26)
    Ask (Size) 2.000 (24)
    Prev. Close 2.020
    Today's Range 1.940 - 2.040
    52wk Range 1.575 - 25.48
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Analyst Ratings For Amylyx Pharma
    Via Benzinga
    NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga

    Performance

    YTD
    -86.67%
    -86.67%
    1 Month
    +12.08%
    +12.08%
    3 Month
    +0.76%
    +0.76%
    6 Month
    -86.42%
    -86.42%
    1 Year
    -91.30%
    -91.30%

    More News

    Read More
    Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?
    Via Benzinga
    Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    6 Analysts Assess Amylyx Pharma: What You Need To Know
    Via Benzinga
    Breaking Down Amylyx Pharma: 9 Analysts Share Their Views
    Via Benzinga
    Unveiling 6 Analyst Insights On Amylyx Pharma
    Via Benzinga
    Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    AMLX Stock Earnings: Amylyx Pharma Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder
    Via Benzinga
    Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    AMLX DEADLINE TOMORROW: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    AMLX DEADLINE TOMORROW: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via TheNewswire.com
    Topics Lawsuit
    Exposures Financial Legal
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    AMLX DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action – AMLX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    AMLX IMPORTANT DEADLINE: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    AMLX IMPORTANT DEADLINE: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via TheNewswire.com
    Topics Lawsuit
    Exposures Financial Legal
    AMLX DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    AMLX DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via TheNewswire.com
    Topics Lawsuit
    Exposures Financial Legal
    AMLX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.